

Regd. Add.: Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22 CIN: L85100MH2008PLC179034, Email: instituteofurology@gmail.com

Website: www.tejnaksh.com | Tel No.: 022 – 2404 4983/ 2404 4984

14.02,2020

To, **BSE Limited**Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter and Nine Months ended on 31st December, 2019.

Please find the enclosed herewithUn-Audited Financial Results (Standalone & Consolidated) for the Quarterand Nine Months ended on 31<sup>st</sup> December, 2019along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on Friday, 14<sup>th</sup>February, 2020 at Lion TarachandBapa Hospital, Lion TarachandBapa Hospital Marg, Sion - West, Mumbai – 400 033 at 1.00 p.m.,in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

Showandale

Dr. Preeti Ashish Rawandale

**Director** 

DIN:-02021400

## P.D.DALAL & Co.

### Chartered Accountants

Independent Auditor's Review Report on quarterly Unaudited Standalone Financial Results of Tejnaksh Healthcare Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors Tejnaksh Healthcare Limited

We have reviewed the accompanying Statement of the Unaudited Standalone Financial Results of **Tejnaksh Healthcare Limited** ('the Company') for the quarter ended on 31<sup>st</sup> December 2019 (the Statement) being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with Circular No.CIR/CFC/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with aforesaid accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dates July 5, 2016. including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.D.Dalal & Co., Chartered Accountants Firm Registration No. 102047W

(Aashish S. Kakaria) Partner Membership no. 102915

Mumbai 14<sup>th</sup> February, 2020





Regd. Add.: Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN: L85100MH2008PLC179034, Email: instituteofurology@gmail.com Website: www.tejnaksh.com | Tel No.: 022 – 2404 4983/ 2404 4984

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER / NINE MONTH ENDED DECEMBER, 2019

SI.No.	Particulars	Quarte	er Ended (Rs in '	Lakhs)	Nine Month Ended (Rs in 'Lakhs)		Year Ended (Rs in 'Lakhs)
		December 31,2019	September 30,2019	December 31,2018	December 31,2019	December 31,2018	March 31,2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	REVENUE				- 14		
(a)	Revenue from operations (net)	289.06	285.26	355.08	881.32	1,029.54	1,395.79
(b)	Other income	21.94	26.74	24.02	62.28	57.87	142.45
	Total Revenue (I)	311.00	312.00	379.10	943.60	1,087.41	1,538.24
2	EXPENSES	-					
(a)	Purchases of stock-in-trade	15.26	12.44	20.96	45.43	68.43	80.92
	Changes in inventories of Stock-in-	10.20	12.77	20.90	45.45	00.43	80.92
(b)	Trade	(0.53)	(6.57)	(6.82)	(1.25)	(16.63)	(21.05)
(c)	Employee benefits expense	36.19	39.39	56.98	118.98	148.98	200.40
(d)	Finance costs	17.53	18.05	16.22	55.02	48.11	76.69
(e)	Depreciation and amortization expense	15.20	14.10	13.32	43.19	38.45	52.33
(f)	Other expenses	148.83	150.48	203.12	419.25	579.12	773.96
	Total Expenses (II)	232.47	227.89	303.78	680.61	866.46	1,163.26
3	Profit hotoro toy (I) (II)	78.53	84.11	75.22	262.00	200.05	074.00
3	Profit before tax (I) - (II)	76.53	04.11	75.32	262.99	220.95	374.98
4	Tax expense:						
(a)	Current tax	17.25	15.55	16.50	57.05	48.00	86.15
	Adjustment of tax relating to earlier			1000	n h 1	40.00	00.10
(b)	periods.	-	_		**************************************	1000000	
(c)	Deferred tax	4.72	(2.52)	4.46	5.85	13.68	19.63
	Total Tax Expenses	21.97	13.03	20.96	62.90	61.68	105.78
5	Profit for the Period	56.57	71.08	54.36	200.10	159.27	269.20
6	OTHER COMPREHENSIVE INCOME				$A \subseteq A =$		
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:     B. Other Comprehensive income to be reclassified to profit and loss in subsequent	X.	Trans.			-	-
	periods:	-				2	-
	Other Comprehensive income for the						
	year, net of tax	-	Transfer of the same of the sa	•	3		•
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	56.57	71.08	54.36	200.10	159.27	269.20
		17/2					31.74
7	Paid up Equity Share Capital (Face value	101.57	101.57	101.57	101.57	101.57	101.57
8	Basic and Diluted earnings per share (INR)	0.56	0.70	0.54	1.97	1.57	2.65







Regd. Add.: Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN: L85100MH2008PLC179034, Email: instituteofurology@gmail.com Website: www.tejnaksh.com | Tel No.: 022 – 2404 4983/ 2404 4984

#### Notes:

- 1. The financial result were reviewed by the audit committee and approved by the Board of directors at its meeting held on 14th February, 2020
- 2. There were no investor complaints received / pending as at 31st December, 2019.
- 3. The company does not have more than one reportable segment, hence segment wise reporting is not applicable.

Place: Mumbai Date: 14.02.2020 For and on behalf of board of Directors Tejnaksh Healthcare Limited

(Dr. P.A. Rawandale)

Director DIN: 02021400

# P.D.DALAL & Co.

## Chartered Accountants

Independent Auditor's Review Report on quarterly Unaudited Consolidated Financial Results of Tejnaksh Healthcare Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors Tejnaksh Healthcare Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Tejnaksh Healthcare Limited** ('the Parent') and its subsidiary **Tejvedaant Healthcare Private Limited** ('the Subsidiary') together referred to as 'the Group' and its share of the profit after tax and total comprehensive profit of its subsidiary for the quarter ended on 31st December 2019 (the Statement) being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with Circular No.CIR/CFC/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with aforesaid accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dates July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.D.Dalal & Co., Chartered Accountants Firm Registration No. 102047W

(Aashish S. Kakaria)
Partner
Membership no. 102915

+ Scakans

Mumbai 14<sup>th</sup> February, 2020





Regd. Add.: Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN: L85100MH2008PLC179034, Email: instituteofurology@gmail.com Website: www.tejnaksh.com | Tel No.: 022 – 2404 4983/ 2404 4984

### STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTH ENDED DECEMBER, 2019

SI.No.	Particulars	Quarte	r Ended (Rs in 'La	akhs)	Nine Month Ended (Rs in 'Lakhs)		Year Ended (Rs in 'Lakhs)
		December 31,2019	September 30,2019 (Unaudited)	December 31,2018 (Unaudited)	December 31,2019 (Unaudited)	December 31,2018 (Unaudited)	March 31,2019 (Audited)
		(Unaudited)					
1	REVENUE						
(a)	Revenue from operations (net)	429.32	445.82	515.50	1,320.96	1,463.80	1,975.73
(b)	Other income	19.14	24.59	37.28	54.25	76.00	154.92
	Total Revenue (I)	448.46	470.41	552.78	1,375.21	1,539.80	2,130.65
2	EXPENSES			-			
(a)	Purchases of stock-in-trade	29.85	28.95	36.90	94.00	102.59	130.65
	Changes in inventories of Stock-in-						
(b)	Trade	1.66	(5.58)	(2.25)	4.40	(3.41)	
(c)	Employee benefits expense	64.76	57.96	79.47	188.21	219.62	The state of the s
(d)	Finance costs	17.78	18.67	16.60	56.31	48.52	
(e)	Depreciation and amortization expense	16.95	15.79	14.99	48.28	43.31	58.81
(f)	Other expenses	234.70	251.29	316.18	694.51	869.70	
	Total Expenses (II)	365.70	367.08	461.89	1,085.72	1,280.33	1,694.28
3	Profit before tax (I) - (II)	82.77	103.33	90.89	289.48	259.47	436.37
					1		
4	Tax expense:	40.00	20.04	20.55	63.56	57.15	100.70
(a)	Current tax	18.68	20.04	20.55	63.36	37.13	100.70
(b)	Adjustment of tax relating to earlier perio	5.00	(2.55)	6.24	6.36	15.66	22.00
(c)	Deferred tax	5.00	(2.55)	26.79	69.91	72.81	122.70
	Total Tax Expenses	23.68	17.49	64.10	219.57	186.66	313.67
5	Profit for the year	59.08	85.84	04.10	219.57	100.00	313.07
6	OTHER COMPREHENSIVE INCOME				TENNY CONTRACTOR		
	A Other Commencing income not to be						
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent						
	periods:	<u>_</u>			- AN	-	-
	B. Other Comprehensive income to be	,63					
	reclassified to profit and loss in subsequent			Th. 1/2			
	periods:		_	440	/	-	-
	Other Comprehensive income for the year,		40	2017 N. 7			
	net of tax			4 4 3 V Y 1	-		-
	TOTAL COMPREHENSIVE INCOME FOR		49				
	THE PERIOD, NET OF TAX	59.08	85.84	64.10	219.57	186.66	313.67
7	Profit for the year attributable to:	58.45	82.16	61.66	214.70	179.81	302.55
	Equity holders of the parent	0.63	3.69	2.44	4.87	6.85	A CONTRACTOR OF THE PROPERTY O
	Non-controlling interests	0.63	3.09	2.44	4.07	0.00	11.12
	Total comprehensive income for the year	15					
8	attributable to:		1000000				
	Equity holders of the parent	58.45	82.16	61.66	214.70	179.81	302.55
	Non-controlling interests	0.63	3.69	2.44	4.87	6.85	11.12
9	Paid up Equity Share Capital (Face value	101.57	101.57	101.57	101.57	101.57	101.57
	Basic and Diluted earnings per share						







Regd. Add.: Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN: L85100MH2008PLC179034, Email: instituteofurology@gmail.com Website: www.tejnaksh.com | Tel No.: 022 - 2404 4983/ 2404 4984

### Notes:

- 1. The financial result were reviewed by the audit committee and approved by the Board of directors at its meeting held on 14th February ,2020
- 2. There were no investor complaints received / pending as at 31st December, 2019.
- 3. The consolidated unaudited financial result relates to Tejnaksh Healthcare Limited, the Holding Company and its subsidiary Tejvedaant Healthcare Private Limited.
- 4. The company does not have more than one reportable segment, hence segment wise reporting is not applicable.

Place: Mumbai Date: 14.02.2020 For and on behalf of board of Directors

Tejnaksh Healthcare Limited,

Director DIN: 02021400